OSE Immunotherapeutics Reports its Cash Position as of June 30, 2026, and Provides Business Update
Filed with Euronext · · 4 pages · English
• The Company continues to engage actively with institutional investors in the United States and Europe to extend its cash runway beyond key upcoming value inflection points • In this context, publication of first half 2026 financial results is postponed • Enrolment of Tedopi’s Phase 3 clinical trial ARTEMIA in lung cancer on track for completion by end of December 2026; planned futility analysis
OSE Immunotherapeutics SA on 6ix
In the deck
Story so far
Earlier from OSE Immunotherapeutics
- OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
- OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
- OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipients
- OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le pegrizeprument (VEL-101) dans la prévention du rejet d’organe chez les patients transplantés rénaux
- Informations relatives au nombre total de droits de vote et d’actions composant le capital
Later from OSE Immunotherapeutics
- OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
- OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
Follow OSE Immunotherapeutics into a list and get an email when it puts out news.
Follow OSE Immunotherapeutics